Dr. Peter B. Bach's presentation from "What Soaring Drug Prices Mean for Patients," 9.3.15
http://www.reportingonhealth.org/content/what-soaring-drug-prices-mean-patients
Top Rated Bangalore Call Girls Richmond Circle ⟟ 9332606886 ⟟ Call Me For Ge...
Dr. Peter B. Bach: "What Soaring Drug Prices Mean for Patients," 9.3.15
1. Some questions about high
drug prices
Peter B. Bach, MD
Center for Health Policy and Outcomes
Memorial Sloan Kettering Cancer Center
bachp@mskcc.org
@peterbachmd
September 3, 2015
7. Two drugs (peter’s crude assessment)
Farydak (Feb 2015 approval) Ibrance (Feb 2015 approval)
Price: $10,035 per month
•FDA path: Squeaked through (voted
down by ODAC advisors 5 to 2).
• Use: 3rd line multiple myeloma
•(11,000 deaths per year)
• Benefit: Increased PFS by 5 months,
but not overall survival
• Tolerability: Severe side effects with a
“Black Box”
Price: $9,978 per month
•FDA path: Accelerated approval
from impressive Phase 2 data
•Use: 1st line metastatic breast cancer
(larger health problem, 40K deaths/yr)
•Benefit: Increased PFS by 10 months,
survival data pending
• Tolerability: Moderate side effects
9. Product prices rise even as:
a) competitors enter the market
b) new indications are added
Gleevec Tablet
Year
2004 2006 2008 2010 2012 2014
Averagecostperday($2014)
0
50
100
150
200
250
Nilotinib approved
Dasatinib approved
Multiple additional
indications approved
10. The reason why US Pharma is such
a great sector?
Because we pay high prices in the
US.
17. Or what about prices based on ‘value’?
• Who cares about value?
– Patients: Benefits and side effects of
treatment
– Academia and Industry: Promote innovation
and risk-taking, support the costs of research
– Society:Target rare disease, tackle public
health problems